A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
Conclusions
These promising safety and efficacy results, including the encouraging 12-month 34.9% combined OS rate, warrant further investigation of ADXS11-001 for treatment of recurrent/refractory cervical cancer.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Cervical Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Immunotherapy | Listeria | Study